Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
Phase 2
- Conditions
- Non-small-cell Lung Cancer
- Interventions
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT03267654
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital;, Shanghai, Shanghai, China
A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients
Phase 1
- Conditions
- Chronic Hepatitis b
- Interventions
- Drug: QL-007 tablet
- First Posted Date
- 2017-08-09
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03244085
- Locations
- 🇳🇿
P3 Research, Wellington, New Zealand
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT03195569
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tainjin, China
Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer
Phase 3
Completed
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 535
- Registration Number
- NCT03169335
- Locations
- 🇨🇳
Tianjin Chest hospital, Tianjin, China
🇨🇳Shanghai Chest hospital, Shanghai, China
A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer
Phase 1
- Conditions
- Advanced Breast Cancer
- Interventions
- Drug: selatinib ditosilate tablets
- First Posted Date
- 2013-08-30
- Last Posted Date
- 2013-08-30
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT01931943
- Locations
- 🇨🇳
Cancer Institute and Hospital,Chinese Academy of Medical Sciences, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath